Pyraclostrobin


ToxCast endpoints for intended target type: RNA
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CLD_CYP1A2_24hrLiverHuman1544CYP1A2Gain0.42 μM
CLD_ABCB11_48hrLiverHuman8647ABCB11Gain35.3 μM
CLD_CYP1A2_48hrLiverHuman1544CYP1A2Gain0.56 μM
CLD_GSTA2_48hrLiverHuman2939GSTA2Gain33.76 μM
LTEA_HepaRG_ABCB11LiverHuman8647ABCB11Activatory38.4 μM
LTEA_HepaRG_ACOX1LiverHuman51ACOX1Activatory77.78 μM
LTEA_HepaRG_ADKLiverHuman132ADKActivatory77.78 μM
LTEA_HepaRG_BADLiverHuman572BADInhibitory84.67 μM
LTEA_HepaRG_BAXLiverHuman581BAXInhibitory66.67 μM
LTEA_HepaRG_BCL2LiverHuman596BCL2Inhibitory89.89 μM
LTEA_HepaRG_BIDLiverHuman637BIDActivatory75.32 μM
LTEA_HepaRG_CASP3LiverHuman836CASP3Inhibitory79.45 μM
LTEA_HepaRG_CASP8LiverHuman841CASP8Activatory80.12 μM
LTEA_HepaRG_CATLiverHuman847CATActivatory68.38 μM
LTEA_HepaRG_CDKN1ALiverHuman1026CDKN1AActivatory78.99 μM
LTEA_HepaRG_CYP2B6LiverHuman1555CYP2B6Inhibitory78.11 μM
LTEA_HepaRG_CYP2C19LiverHuman1557CYP2C19Activatory77.84 μM
LTEA_HepaRG_CYP2C8LiverHuman1558CYP2C8Activatory77.85 μM
LTEA_HepaRG_CYP2C9LiverHuman1559CYP2C9Activatory74.66 μM
LTEA_HepaRG_CYP2E1LiverHuman1571CYP2E1Inhibitory33.99 μM
LTEA_HepaRG_CYP3A4LiverHuman1576CYP3A4Inhibitory78.46 μM
LTEA_HepaRG_CYP3A5LiverHuman1577CYP3A5Inhibitory87.0 μM
LTEA_HepaRG_CYP3A7LiverHuman1551CYP3A7Activatory74.04 μM
LTEA_HepaRG_CYP7A1LiverHuman1581CYP7A1Activatory71.92 μM
LTEA_HepaRG_DDIT3LiverHuman1649DDIT3Activatory60.9 μM
LTEA_HepaRG_FABP1LiverHuman2168FABP1Activatory80.41 μM
LTEA_HepaRG_FASLiverHuman355FASActivatory78.29 μM
LTEA_HepaRG_FMO3LiverHuman2328FMO3Inhibitory75.67 μM
LTEA_HepaRG_FOXO1LiverHuman2308FOXO1Activatory50.0 μM
LTEA_HepaRG_GADD45ALiverHuman1647GADD45AActivatory59.97 μM
LTEA_HepaRG_GADD45GLiverHuman10912GADD45GActivatory79.54 μM
LTEA_HepaRG_GCLCLiverHuman2729GCLCInhibitory80.83 μM
LTEA_HepaRG_GCLMLiverHuman2730GCLMActivatory50.0 μM
LTEA_HepaRG_GSTA2LiverHuman2939GSTA2Activatory78.66 μM
LTEA_HepaRG_GSTM3LiverHuman2947GSTM3Inhibitory80.31 μM
LTEA_HepaRG_HIF1ALiverHuman3091HIF1AActivatory50.0 μM
LTEA_HepaRG_HMGCS2LiverHuman3158HMGCS2Activatory75.26 μM
LTEA_HepaRG_ICAM1LiverHuman3383ICAM1Inhibitory81.22 μM
LTEA_HepaRG_IGF1LiverHuman3479IGF1Activatory68.13 μM
LTEA_HepaRG_IGFBP1LiverHuman3484IGFBP1Activatory64.34 μM
LTEA_HepaRG_IL6LiverHuman3569IL6Inhibitory83.87 μM
LTEA_HepaRG_KCNK1LiverHuman3775KCNK1Activatory86.22 μM
LTEA_HepaRG_LIPCLiverHuman3990LIPCActivatory50.0 μM
LTEA_HepaRG_MIR122LiverHuman406906MIR122Inhibitory76.06 μM
LTEA_HepaRG_MMP10LiverHuman4319MMP10Inhibitory78.09 μM
LTEA_HepaRG_NQO1LiverHuman1728NQO1Activatory84.78 μM
LTEA_HepaRG_PTENLiverHuman5728PTENActivatory78.53 μM
LTEA_HepaRG_SLC22A1LiverHuman6580SLC22A1Activatory58.7 μM
LTEA_HepaRG_SLCO1B1LiverHuman10599SLCO1B1Activatory75.87 μM
LTEA_HepaRG_SULT2A1LiverHuman6822SULT2A1Inhibitory78.68 μM
LTEA_HepaRG_TGFALiverHuman7039TGFAInhibitory78.52 μM
LTEA_HepaRG_TGFB1LiverHuman7040TGFB1Activatory50.0 μM
LTEA_HepaRG_TIMP1LiverHuman7076TIMP1Inhibitory68.45 μM
LTEA_HepaRG_TNFRSF1ALiverHuman7132TNFRSF1AActivatory77.05 μM
LTEA_HepaRG_TP53LiverHuman7157TP53Activatory78.5 μM
LTEA_HepaRG_UGT1A1LiverHuman54658UGT1A1Inhibitory82.45 μM
LTEA_HepaRG_UGT1A6LiverHuman54578UGT1A6Inhibitory73.28 μM

ToxCast endpoints for intended target type: Protein
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
CCTE_Deisenroth_5AR_NBTE_ratioKidneyHuman6716SRD5A2Activatory34.07 μM
ATG_BRE_CISLiverHuman4086SMAD1Inhibitory0.7 μM
ATG_C_EBP_CISLiverHuman1051CEBPBActivatory0.4 μM
ATG_CRE_CISLiverHuman10488CREB3Activatory0.53 μM
ATG_DR5_RAR_CISLiverHuman5914|5915|5916RARA|RARB|RARGActivatory0.64 μM
ATG_Ets_CISLiverHuman2113ETS1Inhibitory1.47 μM
ATG_MRE_CISLiverHuman4520MTF1Activatory2.49 μM
ATG_NF_kB_CISLiverHuman4790NFKB1Inhibitory2.04 μM
ATG_NRF2_ARE_CISLiverHuman4780NFE2L2Activatory0.63 μM
ATG_Oct_MLP_CISLiverHuman5451POU2F1Inhibitory0.7 μM
ATG_PBREM_CISLiverHuman9970NR1I3Activatory1.66 μM
ATG_PPRE_CISLiverHuman5465|5467|5468PPARA|PPARD|PPARGInhibitory0.34 μM
ATG_PXRE_CISLiverHuman8856NR1I2Inhibitory1.26 μM
ATG_RORE_CISLiverHuman6095|6096|6097RORA|RORB|RORCActivatory2.2 μM
ATG_VDRE_CISLiverHuman7421VDRInhibitory1.29 μM
ATG_PPARg_TRANSLiverHuman5468PPARGGain0.59 μM
BSK_BE3C_uPALungHuman5328PLAUInhibitory0.15 μM
BSK_CASM3C_ThrombomodulinVascularHuman7056THBDInhibitory31.21 μM
BSK_hDFCGF_CollagenIIISkinHuman1281COL3A1Inhibitory0.8 μM
BSK_hDFCGF_PAI1SkinHuman5054SERPINE1Inhibitory2.46 μM
BSK_KF3CT_MCP1SkinHuman6347CCL2Inhibitory0.91 μM
BSK_LPS_IL1aVascularHuman3552IL1AInhibitory0.16 μM
BSK_LPS_PGE2VascularHuman5732PTGER2Inhibitory0.21 μM
BSK_SAg_IL8VascularHuman3576CXCL8Inhibitory1.24 μM
NVS_ADME_hCYP1A1Human1543CYP1A1Loss1.87 μM
NVS_ADME_hCYP1A2Human1544CYP1A2Loss0.88 μM
NVS_ADME_hCYP2C18Human1562CYP2C18Loss0.78 μM
NVS_ADME_hCYP2C19Human1557CYP2C19Loss0.72 μM
NVS_ADME_hCYP2C9Human1559CYP2C9Loss1.15 μM
NVS_ADME_rCYP2C11Rat29277Cyp2c11Loss0.81 μM
NVS_ADME_rCYP3A1Rat25642Cyp3a23-3a1Loss1.28 μM
NVS_GPCR_h5HT7Human3363HTR7Loss0.82 μM
NVS_GPCR_hOpiate_muHuman4988OPRM1Loss0.88 μM
NVS_MP_hPBRIntestinalHuman706TSPOLoss0.1 μM
NVS_MP_rPBRKidneyRat24230TspoLoss0.26 μM
ATG_hPPARg_XSP1LiverHuman5468PPARGGain2.02 μM
ATG_hTRa_XSP1LiverHuman7067THRAGain1.51 μM
ATG_mPPARg_XSP2LiverHuman19016PpargGain1.43 μM
ATG_hPPARg_XSP2LiverHuman5468PPARGGain1.15 μM
TOX21_AR_BLA_Antagonist_ratioKidneyHuman367ARLoss1.48 μM
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881BreastHuman367ARLoss0.8 μM
TOX21_Aromatase_LUC_AntagonistBreastHuman1588CYP19A1Loss57.19 μM
TOX21_ERa_BLA_Antagonist_ratioKidneyHuman2099ESR1Loss32.74 μM
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2BreastHuman2099ESR1Loss0.8 μM
TOX21_TR_LUC_GH3_AntagonistPituitary glandRat7067|7068THRA|THRBLoss0.08 μM
TOX21_VDR_BLA_Antagonist_ratioKidneyHuman1591|7421CYP24A1|VDRLoss38.31 μM
TOX21_RORg_LUC_CHO_AntagonistOvaryChinese hamster6097RORCLoss0.37 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881BreastHuman367ARLoss1.02 μM
TOX21_RAR_LUC_AntagonistEmbryoMouse5914RARALoss0.14 μM
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2BreastHuman2099ESR1Loss0.84 μM
TOX21_ERR_LUC_AntagonistKidneyHuman2101ESRRALoss0.22 μM
TOX21_PGC_ERR_LUC_AntagonistKidneyHuman2101ESRRALoss0.42 μM
TOX21_ERb_BLA_Antagonist_ratioKidneyHuman2100ESR2Loss1.26 μM
TOX21_TR_LUC_GH3_Antagonist_FollowupPituitary glandRat7067|7068THRA|THRBLoss1.09 μM
TOX21_TR_RXR_BLA_Antagonist_Followup_ratioKidneyHuman6256RXRALoss38.31 μM
TOX21_SBE_BLA_Antagonist_ratioKidneyHuman4086SMAD1Loss39.18 μM
TOX21_p450_CYP2C19_AntagonistHuman1557CYP2C19Loss0.64 μM
TOX21_p450_CYP1A2_AntagonistHuman1544CYP1A2Loss1.02 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
APR_HepG2_MitoticArrest_72hrLiverHuman3020H3-3AInhibitory39.93 μM
OT_FXR_FXRSRC1_0480KidneyHuman6714|9971SRC|NR1H4Gain1.54 μM
OT_FXR_FXRSRC1_1440KidneyHuman6714|9971SRC|NR1H4Gain1.45 μM
ACEA_AR_antagonist_80hrProstateHuman367ARLoss33.48 μM
TOX21_ARE_BLA_Agonist_ratioLiverHuman4780NFE2L2Gain0.37 μM
TOX21_FXR_BLA_Antagonist_ratioKidneyHuman9971NR1H4Loss2.25 μM
TOX21_PPARg_BLA_Antagonist_ratioKidneyHuman5468PPARGLoss0.73 μM
TOX21_p53_BLA_p2_ratioIntestinalHuman7157TP53Gain1.09 μM
TOX21_p53_BLA_p3_ratioIntestinalHuman7157TP53Gain1.51 μM
TOX21_p53_BLA_p4_ratioIntestinalHuman7157TP53Gain1.67 μM
TOX21_p53_BLA_p5_ratioIntestinalHuman7157TP53Gain1.9 μM
TOX21_SHH_3T3_GLI3_LUC_AntagonistEmbryoMouse6469SHHLoss0.06 μM

ToxCast endpoints for intended target type: Cellular
Assay NameTissueOrganismTarget Gene IDTarget HGNC SymbolResponseAC50 Value
APR_HepG2_MicrotubuleCSK_72hrLiverHuman7846TUBA1AInhibitory1.11 μM

No ToxCast endpoints for intended target type: Hormone
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.